Localised prostate cancer: Can we do better?: There have been some advances in local control, but little impact on survival

BMJ

Volumn 320, Issue 7227, 2000, Pages 69-70

  Prior, Tova ^a   Waxman, Jonathan ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; LUTEINIZING HORMONE; PALLADIUM; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE IODINE;

BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HOT FLUSH; HUMAN; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SEXUAL DYSFUNCTION;

FEMALE; GREAT BRITAIN; HUMANS; MALE; PATIENT SELECTION; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0034620276     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.320.7227.69     Document Type: Editorial

References (16)

1. Brawley OW. Prostate carcinoma incidence and patient mortality: The effects of screening and early detection. Cancer 1997; 80: 1857–1863.
2. Imperato PJ, Nenner RP, Will TO. Trends in radical prostatectomy in New York State. Am J Med Qual 1996; 11: 205–213.
3. Gerber GS, Thisted RA, Scardino PT, Frohmuller HGW, Schroeder FH, Paulson DF, et al. Results of radical prostatectomy in men with clinically localised prostate cancer. JAMA 1996; 276: 615–619.
4. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localised prostate carcinoma. Cancer 1997; 79: 337–344.
5. Chodak GW, Thisted RA, Gerber GS, Johansson J-E, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localised prostate cancer. N Engl J Med 1994; 330: 242–248.
6. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343: 251–254.
7. Feneley MR, Gillatt DA, Hehir M, Kirby RS. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome. Br J Urol 1996; 78: 911–920.
8. Jonler M, Madsen SA, Rhodes PR, Sall M, Messing EM, Bruskewitz RC. A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retro-pubic prostatectomy. Urology 1996; 48: 433–440.
9. Zietman AL, Prince EA, Nakfoor BM, Shipley WU. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology 1997; 49 (suppl 3A): 74–83.
10. D'Amico AV, Coleman CN. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: The jury is still out. J Clin Oncol 1996; 14: 304–315.
11. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999; 353: 267–272.
12. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491–500.
13. Lee HHK, Warde P, Jewett MAS. Neoadjuvant hormonal therapy in carcinoma of the prostate. Br J Urol 1999; 83: 438–448.
14. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RLS, Sause WT, et al. Androgen deprivation with radiotherapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomised comparative trial of RTOG. Urology 1995; 45: 616–623.
15. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and Goserelin. New Engl J Med 1997; 337: 295–300.
16. Vicini FA, Kini VR, Spencer W, Martinez AA. The role of androgen deprivation in the definitive management of clinically localised prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 1999; 43: 707–713.